Correlation Analysis
Alnylam Pharmaceuticals, Inc. vs Mastercard Incorporated
ALNY vs MA
+0.757
Strong positive
When one moves up, the other tends to follow.
Alnylam Pharmaceuticals, Inc.
↗ALNY
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Market cap 43.8B · 2,500 employees
Mastercard Incorporated
↗MA
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
Market cap 447.2B
Time Series
Relative Performance
Who Moves First
MA leads ALNY by 4 days
MA tends to move before ALNY.
After testing 13 timing shifts, the strongest relationship was +0.758 (they moved in the same direction).
Do They Crash Together?
Correlation by Market Regime
How these series behave when markets are rising, falling, or diverging. A correlation that holds in drawdowns is very different from one that only works in rallies.
Both Rising
-0.002
10 periods · Return correlation when both series rose
Both Falling
+0.348
9 periods · Return correlation when both series fell
Diverging
-0.506
16 periods · Return correlation when series moved apart
R-Squared
57.3%
Share of variance in one series explained by the other.
Trend Agreement
59.3%
How often both series moved in the same direction period-to-period.
Overlap Quality
1,253
Deep shared window — 1,253 usable pairs.
Significance
p < 0.001
95% CI: [0.732, 0.780]
Scatter
XY Regression
Pipeline
Data quality details
Pipeline
Data quality details
Pipeline Summary
1,253 paired data points survived the daily window.
Raw input
1,253
1,254
Normalized
1,253
1,254
Prepared
1,253
1,254
Aligned
1,253
1,253
Invalid removed
0
A: 0 / B: 0
Duplicates removed
0
A: 0 / B: 0
Alignment drops
1
A: 0 / B: 1
Series A
Alnylam Pharmaceuticals, Inc.
ALNY
Market cap 43.8B · 2,500 employees
Stock · 1,253 raw → 1,253 prepared
Series B
Mastercard Incorporated
MA
Market cap 447.2B
Stock · 1,254 raw → 1,254 prepared
Sign agreement
100.0%
How often both values share the same sign.
Zero crossings
53
Estimated crossover points between normalized spreads.
Slope
0.7572
Linear regression slope.
Intercept
258.9189
Linear regression intercept.
Related Extremes
Highest and Lowest Correlated
Saved 6 hours ago · ID: stock-alny-vs-stock-ma-daily